# A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma

> **NCT05138146** · PHASE2 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** 609A
- **DRUG:** doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT05138146
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-30
- **Primary completion:** 2023-11-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05138146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05138146, "A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05138146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*